Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1756 to 1770 of 9020 results

  1. Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]

    Awaiting development Reference number: GID-TA11748 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]

    Awaiting development Reference number: GID-TA11754 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development Reference number: GID-TA11501 Expected publication date:  24 February 2027

    Technology appraisal guidance
    In development

  4. Xanomeline tartrate–trospium chloride for treating schizophrenia [ID6716]

    Awaiting development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Luspatercept for treating anaemia caused by myelodysplastic syndromes (including review of TA844) [ID6696]

    Awaiting development Reference number: GID-TA11914 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Pembrolizumab for treating advanced or recurrent endometrial cancer with mismatch repair deficiency [ID6710]

    Awaiting development Reference number: GID-TA11931 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Miniature lens system implantation for advanced age-related macular degeneration

    Awaiting development Reference number: GID-HTG10468 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  8. Managing symptoms with an uncertain cause

    Awaiting development Reference number: GID-QS10103 Expected publication date: TBC

    Quality standard
    Awaiting development

  9. Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

    Awaiting development Reference number: GID-QS10106 Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  08 October 2027

    NICE guideline
    In development

  11. Shared decision-making: practical guidance for health and social care professionals

    Awaiting development Reference number: GID-QS10097 Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Safeguarding adults in care homes

    Awaiting development Reference number: GID-QS10147 Expected publication date: TBC

    Quality standard
    Awaiting development

  13. Supporting independent living and preventing isolation in adults of working age with social care needs

    Awaiting development Reference number: GID-QS10149 Expected publication date: TBC

    Quality standard
    Awaiting development

  14. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development Reference number: GID-TA11154 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]

    Awaiting development Reference number: GID-TA11292 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development